ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia

Alexandria TM Lee,1 Saihong Ignatius Ou1,2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence: Saihong Ignatius Ou, University of California Irvine School of Medicine, Department of Med...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Lee AT, Ou SI
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Dove Medical Press 2023-07-01
Edice:	Lung Cancer: Targets and Therapy
Témata:	alesia crown alectinib lorlatinib brigatinib pharmacokinetics dose response alk fusion nsclc
On-line přístup:	https://www.dovepress.com/alesia-5-year-update-alectinib-at-600-mg-twice-daily-gives-lorlatinib--peer-reviewed-fulltext-article-LCTT
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!